Tina deVries
2021
In 2021, Tina deVries earned a total compensation of $692.8K as Former EVP, Research & Development at RVL Pharmaceuticals plc, a 47% decrease compared to previous year.
Compensation breakdown
| Option Awards | $271,180 |
|---|---|
| Salary | $410,000 |
| Other | $11,600 |
| Total | $692,780 |
deVries received $410K in salary, accounting for 59% of the total pay in 2021.
deVries also received $271.2K in option awards and $11.6K in other compensation.
Rankings
In 2021, Tina deVries' compensation ranked 9,925th out of 12,415 executives tracked by ExecPay. In other words, deVries earned more than 20.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,925 out of 12,415 | 20th |
Division Manufacturing | 4,392 out of 5,505 | 20th |
Major group Chemicals And Allied Products | 1,955 out of 2,375 | 18th |
Industry group Drugs | 1,737 out of 2,096 | 17th |
Industry Pharmaceutical Preparations | 1,293 out of 1,546 | 16th |
Source: SEC filing on April 24, 2023.
deVries' colleagues
We found three more compensation records of executives who worked with Tina deVries at RVL Pharmaceuticals plc in 2021.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019